PRINCETON, N.J., March 22, 2005 -- Bristol-Myers Squibb Company today 
announced the company will extend its relief efforts for two more years to the 
state-administered AIDS Drug Assistance Programs (ADAPs) to help address the 
funding crisis the programs face. Bristol-Myers Squibb has provided, and will 
continue to provide, millions of dollars in relief to ADAPs during the next two 
years by supplying the company's complete line of HIV medications and other 
select products at a reduced cost. This extension will help ensure thousands of 
low-income, underinsured and uninsured people living with HIV/AIDS maintain access 
to life-saving antiretroviral medications.

"Bristol-Myers Squibb is committed to ensuring people living with HIV/AIDS
have access to the medicines they need," said Ron Cooper, senior vice
president, Bristol-Myers Squibb Virology. "To reinforce this commitment, we
are extending our agreement with the ADAPs to help reach that goal."

ADAPs are not entitlement programs (that is, a patient who meets
eligibility criteria is not guaranteed benefits) and, as a result, reduced
state and federal appropriations coupled with growing program demands, have
led to program restrictions and waiting lists for medicines. With 20 to
25 percent of all HIV medications currently purchased through state ADAPs and
the number growing, finding long-term solutions to the funding crisis is
critical.

Through this extension, Bristol-Myers Squibb will continue to provide its
entire portfolio of HIV medications at a reduced cost to ADAPs through March
2007. This assistance will provide states the opportunity to access the
company's once-daily therapies used in combination treatment including
REYATAZ( (atazanavir sulfate) (100 mg, 150 mg, 200 mg), the first once-daily
protease inhibitor, and SUSTIVA (efavirenz) (50 mg, 100 mg, 200 mg,
600 mg), the only non-nucleoside reverse transcriptase inhibitor to be
recommended as part of a "preferred regimen" for the initial treatment of HIV
by the U.S. Department of Health and Human Services.

Bristol-Myers Squibb has worked to be a catalyst for change in the lives
of people with HIV/AIDS through a wide range of programs. Through the Patient
Assistance Program, the company provides free medications to low-income
individuals who do not qualify for prescription drug assistance through public
or private sources including ADAPs and Medicaid. This program serves as a
final safety net for patients with no means to access medicine.